LETTER TO THE EDITOR
Caution should be exercised when assessing ivermectin for the treatment of COVID-19 in systematic reviews
Jiawen Deng,
Fangwen Zhou,
Kiyan Heybati,
Kyra Kavanagh,
Corresponding Author
Jiawen Deng
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Correspondence
Jiawen Deng, Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
Email: [email protected]
Search for more papers by this authorFangwen Zhou
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorKiyan Heybati
Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorKyra Kavanagh
Faculty of Science, Carleton University, Ottawa, Ontario, Canada
Search for more papers by this authorJiawen Deng,
Fangwen Zhou,
Kiyan Heybati,
Kyra Kavanagh,
Corresponding Author
Jiawen Deng
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Correspondence
Jiawen Deng, Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada.
Email: [email protected]
Search for more papers by this authorFangwen Zhou
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorKiyan Heybati
Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorKyra Kavanagh
Faculty of Science, Carleton University, Ottawa, Ontario, Canada
Search for more papers by this authorFirst published: 09 December 2021
No abstract is available for this article.
Open Research
DATA AVAILABILITY STATEMENT
No data is disseminated through this publication.
REFERENCES
- 1Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from COVID-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies. Rev Med Virol. 2021:e2265. https://doi.org/10.1002/rmv.2265
- 2Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. https://doi.org/10.1136/bmj.n71
- 3Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2008.
- 4Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17(1): 1-12. https://doi.org/10.1016/0197-2456(95)00134-4
- 5Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020. https://doi.org/10.1101/2020.10.26.20219345
10.1101/2020.10.26.20219345 Google Scholar
- 6Podder CS, Chowdhury N, Sina MI, Haque W. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study. IMC J Med Sci. 2020; 14(2): 11-18.
10.3329/imcjms.v14i2.52826 Google Scholar
- 7Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. https://doi.org/10.21203/rs.3.rs-100956/v4
10.21203/rs.3.rs?100956/v4 Google Scholar
- 8Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. https://doi.org/10.1136/bmj.d5928
- 9Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. https://doi.org/10.1136/bmj.l4898
- 10Hartling L, Bond K, Vandermeer B, Seida J, Dryden DM, Rowe BH. Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma. PLoS One. 2011; 6(2):e17242. https://doi.org/10.1371/journal.pone.0017242
- 11Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924-926. https://doi.org/10.1136/bmj.39489.470347.AD
- 12Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. https://doi.org/10.1186/1471-2288-14-135
- 13Shi J, Luo D, Wan X, et al. Detecting the skewness of data from the sample size and the five-number summary. arXiv. 2020. http://arxiv.org/abs/2010.05749
- 14López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. J Am Med Assoc. 2021; 325(14): 1426-1435. https://doi.org/10.1001/jama.2021.3071
- 15Shouman W. Prophylactic Ivermectin in COVID-19 Contacts. NIH US Library of Medicine ClinicalTrials.gov; 2021. Accessed 2021. https://clinicaltrials.gov/ct2/show/NCT04422561
- 16Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021; 32:100720. https://doi.org/10.1016/j.eclinm.2020.100720
- 17Schiavo JH. PROSPERO: an international register of systematic review protocols. Med Ref Serv Q. 2019; 38(2): 171-180. https://doi.org/10.1080/02763869.2019.1588072
- 18Paez A. Grey literature: an important resource in systematic reviews. J Evid Based Med. 2017. https://doi.org/10.1111/jebm.12265
10.1111/jebm.12266 Google Scholar
- 19Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med. 2021:bmjebm. https://doi.org/10.1136/bmjebm-2021-111678
10.1136/bmjebm?2021?111678 Google Scholar
- 20Hill A, Garratt A, Levi J, et al. Erratum: expression of concern: “meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection”. Open Forum Infect Dis. 2021; 8(8):ofab394. https://doi.org/10.1093/ofid/ofab394
- 21Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021. https://doi.org/10.1093/qjmed/hcab247
10.1093/qjmed/hcab247 Google Scholar
- 22Kishoria N, Mathur SL, Parmar V, et al. Ivermectin as adjuvant to hydroxychloroquine in patients resistant to standard treatment for sars-cov-2: results of an open-label randomized clinical study. Paripex - Indian J Res. 2020; 9(8): 50-54. https://doi.org/10.36106/paripex/4801859
10.36106/paripex/4801859 Google Scholar
- 23Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. International Journal of Sciences. 2020; 9: 31-35. https://doi.org/10.18483/ijSci.2378
10.18483/ijSci.2378 Google Scholar
- 24Das S, Chatterjee SS. Cabell’s blacklist: a new way to tackle predatory journals. Indian J Psychol Med. 2018; 40(2): 197-198. https://doi.org/10.4103/IJPSYM.IJPSYM_290_17
- 25Beall J. Potential Predatory Scholarly Open-Access Journals. Beall’s List of Potential Predatory Journals and Publishers; 2021. Accessed September 22, 2021. https://beallslist.net/standalone-journals/
- 26Grudniewicz A, Moher D, Cobey KD, et al. Predatory journals: no definition, no defence. Nature. 2019; 576(7786): 210-212. https://doi.org/10.1038/d41586-019-03759-y
- 27Richtig G, Berger M, Lange-Asschenfeldt B, Aberer W, Richtig E. Problems and challenges of predatory journals. J Eur Acad Dermatol Venereol. 2018; 32(9): 1441-1449. https://doi.org/10.1111/jdv.15039
- 28Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. https://doi.org/10.1016/j.antiviral.2020.104787
- 29Peña-Silva R, Duffull SB, Steer AC, Jaramillo-Rincon SX, Gwee A, Zhu X. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br J Clin Pharmacol. 2021; 87(3): 1589-1590. https://doi.org/10.1111/bcp.14476
- 30Fernández-Cruz A, Ruiz-Antorán B, Múñez-Rubio E, et al. The right time for steroids in COVID-19. Clin Infect Dis. 2021; 72(8): 1486-1487. https://doi.org/10.1093/cid/ciaa865
